机译:MA16.06期I / II研究AC0010,突变选择性EGFR抑制剂,非小细胞肺癌(NSCLC)患者EGFR T790M突变患者
Guangdong Lung Cancer Institute Guangdong General Hospital (GGH)and Guangdong Academy of Medical;
Guangdong Lung Cancer Institute Guangdong General Hospital (GGH)and Guangdong Academy of Medical;
Affiliated Hospital of Academy of Military Medical Science;
Department of Respiratory Diseases Peking Union Medical College Hospital Peking Union Medical;
Department of Respiratory Disease Thoracic Disease Center the First Affiliated Hospital College;
Department of Thoracic Medical Oncology Peking University School of Oncology Beijing Cancer;
Department of Thoracic Medicine the Affiliated Cancer Hospital of Xiangya School of Medicine;
Jilin Province Cancer Hospital;
Clinical Pharmacology Research Center Peking Union Medical College Hospital Peking Union Medical;
Clinical Pharmacology Research Center Peking Union Medical College Hospital Peking Union Medical;
Clinical Pharmacology Research Center Peking Union Medical College Hospital Peking Union Medical;
Acea Pharmaceutical Research Hangzhou China and Acea Biosciences Inc. San Diego USA;
Acea Pharmaceutical Research Hangzhou China and Acea Biosciences Inc. San Diego USA;
Acea Pharmaceutical Research Hangzhou China and Acea Biosciences Inc. San Diego USA;
机译:MA16.06期I / II研究AC0010,突变选择性EGFR抑制剂,非小细胞肺癌(NSCLC)患者EGFR T790M突变患者
机译:EGFR-TKI的II期研究与AFATINIB在未经T790M的高级NSCLC患者患者患有AFATINIB的患者中重新检查:冈山肺癌研究组试验OLCSG 1403
机译:EGFR酪氨酸激酶抑制剂(TKI)用于患有罕见EGFR突变的晚期非小细胞肺癌(NSCLC)患者:在中国的一项现实研究
机译:接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
机译:TNFAIP8组合对非小细胞肺癌细胞EGFR和IGF-1R信号传导及靶向药物的细胞毒性的影响
机译:选择性基因扩增可检测患有表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)耐药的晚期非小细胞肺癌(NSCLC)患者血浆中的T790M突变
机译:C1-04:RAD001(依维莫司)单药治疗晚期非小细胞肺癌(NSCLC)先前铂类化疗(C)或先前C和EGFR抑制剂(EGFR-1)失败的患者的II期研究